Navigation Links
Press Statement Issued by Ranbaxy Laboratories Limited

GURGAON, India, Feb. 25 /PRNewswire/ -- Ranbaxy has just received a letter and information indicating that all pending and approved ANDAs from Ranbaxy's Paonta Sahib facility have been added to a list maintained under a policy entitled "Application Integrity Policy" or "AIP". Ranbaxy will analyze the letter and other information fully and respond appropriately in a timely manner.

The FDA has said it has no evidence the drugs on the market are substandard and also that they comply with specifications upon testing.

No products from Ranbaxy's other manufacturing facilities are included in the AIP.

Ranbaxy will continue to co-operate with the USFDA. Further, no effort or action will be spared to timely protect key ANDAs from Paonta Sahib, which include some First to File applications.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

    Company Contacts for Media:

    India Contacts:

    Ramesh L. Adige
    President - Corporate Affairs and Global Corporate Communications
    Ranbaxy Laboratories Ltd.
    Plot 90, Sector 32, Gurgaon
    Haryana122001, India
    Tel: +91-124-4135000


    Raghu Kochar
    Director - Corporate Communications
    Ranbaxy Laboratories Ltd.
    Plot 90, Sector 32, Gurgaon
    Haryana122001, India
    Tel: +91-124-4135141 / Mob: 9811617256


    Krishnan Ramalingam
    Sr. Manager - Corporate Communications
    Ranbaxy Laboratories Ltd.
    Plot 90, Sector 32, Gurgaon
    Haryana122001, India
    Tel: +91-124-4135143 / Mob: 9810042540

    USA Contact:

    Charles M. Caprariello
    Vice President, Corporate Communications
    Ranbaxy Inc.
    (609) 720-5615
    email :

SOURCE Ranbaxy Laboratories Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. Clinical depression linked to abnormal emotional brain circuits
4. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
5. Specific antagonism lowers blood pressure
6. Are too many people diagnosed as depressed?
7. Depression Taking Toll on Returning U.S. Vets
8. Doctors Often Miss High Blood Pressure in Kids
9. Pill box organizers increase HIV patients adherence and improve viral suppression
10. Damp, Moldy Homes May Cause Depression
11. Treating depression may improve recovery of heart rate variability following coronary syndromes
Post Your Comments:
(Date:10/13/2015)... ... 13, 2015 , ... T-System and Centegra Health System, a ... department visits per year, today announced the successful and rapid deployment of EV™, ... and financial outcomes. , In less than four days, Centegra Hospitals ...
(Date:10/13/2015)... ... ... Tempe Dental Care, a leading Tempe dentists’ office, celebrates offering gentle, pain free sedation ... than 5 years. A leading cause of emergency room visits, school absences, and missed ... , Sedation dentistry provides an anxiety-free dental experience with safe and ...
(Date:10/13/2015)... , ... October 13, 2015 , ... World Patent ... Snow Blanket, a snow melting invention that helps people in clearing snow away from ... will continue to grow at 3.8% per year," says Scott Cooper, CEO and Creative ...
(Date:10/13/2015)... ... October 13, 2015 , ... According to an ESPN ... orbital fracture when a teammate accidentally elbowed him in the left eye during the ... injury is just one of a series of setbacks, including a knee injury that ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... Saye as the newest professional to introduce the latest development, ThermiVa® temperature controlled ... as a leading professional in Obstetrics and Gynecology and a pioneer in the ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 13, 2015  Synapse Biomedical Inc. ( ) ... (PAS) studying the use of the NeuRx ® ... enroll patients. the United States ... market-approved criteria. The PAS study group met their initial ... study has since expanded the enrollment target to 150 ...
(Date:10/13/2015)... 2015  SeraCare Life Sciences, a leading partner to ... company,s precision medicine business unit has launched its second ... next-generation sequencing (NGS)-based tumor profiling assays.  The Seraseq TM ... mixture of mutations in key oncogenes and tumor suppressor ... , but is offered at five additional allele frequencies. ...
(Date:10/13/2015)... , Oct. 13 2015 ... the addition of the "US & ... 16 Countries (2010-2021)" report to their ... announced the addition of the "US ... - 16 Countries (2010-2021)" report to ...
Breaking Medicine Technology: